Join Atea Pharmaceuticals for a virtual panel discussion featuring several key opinion leaders (KOLs) including:

• Eric Lawitz, MD – Texas Liver Institute, University of Texas Health San Antonio, US
• Anthony Martinez, MD – University of Buffalo, Erie County Medical Center, US
• David Wyles, MD, FIDSA – University of Colorado, Denver Health Medical Center, US
• Joaquin Cabezas, MD – Marques de Valdecilla University Hospital, Santander, Spain
• Jordan Feld, MD, MPH – University of Toronto, Toronto General Hospital, Canada
• Tarik Asselah, MD, PhD – Hôpital Beaujon, University of Paris-Cité, France

The panel of experts will discuss the current challenges for patients with HCV, the results from Atea’s global Phase 2 study evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of HCV and what a new optimized HCV therapy could provide for prescribers and patients. Company management will also discuss the HCV commercial market opportunity and the global Phase 3 clinical development program.

A live question and answer session will follow the formal discussion.